Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Prospective Research Rare Kidney Stones (ProRKS)

NCT02780297 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric hyperoxaluria (EH). The investigator will measure blood and urinary markers of inflammation and determine relationship to the disease course. Cross-comparisons among the disorders will allow us to better evaluate mechanisms of renal dysfunction in these disorders.

Study Locations (11)

Other

  • Landspitali Universtiy Hospital — Reykjavik
  • Shaare Zedek Medica Center — Jerusalem

Alabama

  • University of Alabama @ Birmingham — Birmingham

Florida

  • Mayo Clinic Jacksonville — Jacksonville

Illinois

  • Children's Memorial Hospital — Chicago

Massachusetts

  • Children's Hospital, Harvard Medical School — Boston

Minnesota

  • Mayo Clinic Hyperoxaluria Center — Rochester

New York

  • New York University — New York

Ohio

  • Cincinnati Children's Hosptial Medical Center — Cincinnati

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2016-05
Est. Completion 2026-07

Sponsor

Mayo Clinic

3,246 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02780297

The ClinicalTrials.gov registry entry for NCT02780297 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 3,246 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Dent Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02780297 reports 11 study locations spanning 10 distinct geographic areas — top geographies include Other, Alabama, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02780297 about?

NCT02780297 is a clinical study titled "Prospective Research Rare Kidney Stones (ProRKS)". The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric hyperoxaluria (EH). The invest...

What is the current status of trial NCT02780297?

This trial is currently recruiting. The enrollment target is 220 participants. The study started on 2016-05. Estimated completion is 2026-07.

What conditions does trial NCT02780297 study?

This clinical trial studies the following conditions: Dent Disease, Cystinuria, Hyperoxaluria, Lowe Syndrome, Adenine Phosphoribosyltransferase Deficiency. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT02780297?

This trial is sponsored by Mayo Clinic, which has 3,246 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02780297 being conducted?

This trial has 11 study locations across Alabama, Florida, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial